NervGen Pharma Excels in Clinical Trials and Drug Development

NervGen Pharma (TSE:NGEN) has released an update.

NervGen Pharma Corp. has reported progress in its clinical trials and drug development pipeline for Q2 2024, with a focus on the treatment of nervous system damage. The company is on track to complete enrollment for a Phase 1b/2a trial and has introduced NVG-300, a new drug candidate targeting conditions such as ischemic stroke and ALS. To improve trial participation, NervGen Pharma has modified its study protocol and covered participant travel costs, potentially speeding up the enrollment process and easing patient involvement.

For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.